FDA still wishy-washy on Low-T drugs' pros and cons

With a Sept. 17 meeting on the horizon to discuss the risks and benefits of testosterone-raising meds--so-called Low-T drugs--the FDA has posted a review on the topic. But its stance is neither here nor there: While the agency says it's unconvinced by studies suggesting the hormone carries serious risks, it doesn't have much evidence that the Low-T products taken by millions of American men are all that beneficial for most. More